As of January 22, 2025, Revance Therapeutics (RVNC) has a market cap of $0.38 billion USD. According to our data, Revance Therapeutics is ranked No.6433 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.38 B |
20.07%
|
Dec 31, 2024 | $0.32 B |
-65.42%
|
Dec 29, 2023 | $0.92 B |
-52.38%
|
Dec 30, 2022 | $1.93 B |
13.11%
|
Dec 31, 2021 | $1.70 B |
-42.41%
|
Dec 31, 2020 | $2.96 B |
74.61%
|
Dec 31, 2019 | $1.69 B |
-19.37%
|
Dec 31, 2018 | $2.10 B |
-43.69%
|
Dec 29, 2017 | $3.73 B |
72.71%
|
Dec 30, 2016 | $2.16 B |
-39.40%
|
Dec 31, 2015 | $3.57 B |
101.65%
|
Dec 31, 2014 | $1.77 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Evolus
EOLS
|
$0.89 B |
-0.000 M
|
USA
|
AbbVie
ABBV
|
$298.91 B |
0.013 M
|
USA
|
Pfizer
PFE
|
$147.43 B |
0.004 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.71 B |
-0.006 M
|
USA
|
Teva Pharmaceutical Industries
TEVA
|
$24.96 B |
19.808 M
|
Israel
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
GlaxoSmithKline
GSK
|
$68.21 B |
-0.002 M
|
UK
|
Revance Therapeutics
RVNC
|
$0.38 B |
0.000 M
|
USA
|
Market Cap | = | RVNC Stock Price | * | RVNC Shares Outstanding |
= | $3.65 | * | 0.10 B | |
= | $0.38 B |